Low-Dose semaglutide: a new hope for weight loss in obese adults?

NCT ID NCT07513168

Recruiting now Disease control Sponsor: Asian Institute Of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a low-dose version of the drug semaglutide to help obese adults lose weight and improve heart health. The trial includes 60 Pakistani adults who are obese but do not have diabetes. Participants will receive weekly injections for 24 weeks, along with diet and exercise advice. The goal is to see if this lower dose is both safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (low-dose)
What this could lead to: If successful, this could provide a safe, low-dose option for weight loss and improved heart health in obese adults without diabetes.
What could go wrong: This is a small, early-phase trial with no placebo group, so results may not be definitive. Side effects like nausea or pancreatitis are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMETABOLIC RISK FACTORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOMETABOLIC RISK FACTORS OBESITY WEIGHT REDUCTION

Contacts and locations

Locations

Asian Institute of Medical Sciences
RECRUITING

Hyderābād, Sindh, 71000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.